<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932682</url>
  </required_header>
  <id_info>
    <org_study_id>V130_14</org_study_id>
    <secondary_id>2018-001857-29</secondary_id>
    <nct_id>NCT03932682</nct_id>
  </id_info>
  <brief_title>Efficacy Study With QIVc in Pediatric Subjects</brief_title>
  <official_title>A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus&#xD;
      a non-influenza vaccine in subjects 6 months though 47 months of age. The purpose of this&#xD;
      study is to evaluate efficacy of QIVc in the prevention of Reverse transcription polymerase&#xD;
      chain reaction (RT-PCR) confirmed influenza A or B disease in children 6 through 47 months of&#xD;
      age, compared to a non-influenza vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">September 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial is designed as an observer-blind study. During the treatment period of the study designated and trained unblinded personnel will be responsible for administering the study vaccines to the subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Endpoint: First occurrence of RT-PCR confirmed influenza, due to any influenza Type A and/or B virus regardless of antigenic match</measure>
    <time_frame>Day 14 to Day 180</time_frame>
    <description>First occurrence of RT-PCR confirmed influenza, due to any influenza Type A and/or B virus regardless of antigenic match to the influenza strains selected for the seasonal influenza vaccine, occurring at &gt;14 days after the last vaccination and until the end of the influenza season, in association with protocol-defined influenza-like illness (ILI) symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Endpoint: First occurrence of culture confirmed influenza, due to influenza Type A and/or B virus antigenically matched by ferret antigenicity testing to the strains selected for the seasonal influenza vaccine</measure>
    <time_frame>Day 14 to Day 180</time_frame>
    <description>First occurrence of culture confirmed influenza, due to influenza Type A and/or B virus antigenically matched by ferret antigenicity testing to the strains selected for the seasonal influenza vaccine, occurring at &gt;14 days after the last vaccination and until the end of the influenza season, in association with protocol-defined ILI symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: First occurrence of culture confirmed influenza caused by influenza virus strains antigenically dissimilar to the influenza strains selected for the seasonal influenza vaccine</measure>
    <time_frame>Day 14 to Day 180</time_frame>
    <description>First occurrence of culture confirmed influenza caused by influenza virus strains antigenically dissimilar to the influenza strains selected for the seasonal vaccine occurring at &gt;14 days after the last vaccination and until the end of the influenza season, in association with protocol-defined ILI symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: First occurrence of culture confirmed influenza due to any influenza Type A and/or Type B virus regardless of antigenic match to the influenza strains selected for the seasonal influenza vaccine</measure>
    <time_frame>Day 14 to Day 180</time_frame>
    <description>First occurrence of culture confirmed influenza due to any influenza Type A and/or Type B virus regardless of antigenic match to the influenza strains selected for the seasonal influenza vaccine, occurring at &gt;14 days after the last vaccination and until the end of the influenza season, in association with protocol-defined ILI symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: First occurrence of RT-PCR confirmed moderate-to-severe influenza due to any influenza Type A and/or Type B virus regardless of antigenic match to the influenza strains selected for the seasonal influenza vaccine</measure>
    <time_frame>Day 14 to Day 180</time_frame>
    <description>First occurrence of RT-PCR confirmed moderate-to-severe influenza due to any influenza Type A and/or Type B virus regardless of antigenic match to the influenza strains selected for the seasonal influenza vaccine, occurring at &gt;14 days after the last vaccination and until the end of the influenza season</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: a) Prevaccination and postvaccination Geometric Mean Titer (GMT)</measure>
    <time_frame>Day 1 and 28 days after last vaccination</time_frame>
    <description>The measures for immunogenicity are determined by a haemagglutination inhibition [HI] and/or a microneutralization [MN] assay prior to first vaccination and 28 days after last vaccination for all four influenza strains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Seroconversion rates (SCR)</measure>
    <time_frame>Day 1 and 28 days after last vaccination</time_frame>
    <description>The measures for immunogenicity are determined by a HI and/or a MN assay prior to first vaccination and 28 days after last vaccination for all four influenza strains&#xD;
SCR is defined as the percentage of subjects with either a prevaccination HI (or MN) titer &lt; 1:10 and a postvaccination HI (or MN) titer ≥ 1:40, or a prevaccination HI (or MN) titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI (or MN) titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity endpoint: Geometric Mean Ratio (GMR)</measure>
    <time_frame>Day 1 and 28 days after last vaccination</time_frame>
    <description>The measures for immunogenicity are determined by a haemagglutination inhibition [HI] and/or a micro neutralization [MN] assay prior to first vaccination and 28 days after last vaccination for all four influenza strains&#xD;
GMR is the geometric mean of the fold increase of post-vaccination HI (or MN) titer over the pre-vaccination HI (or MN) titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of subjects with solicited local and systemic adverse events (AE)</measure>
    <time_frame>7 days following each vaccination</time_frame>
    <description>Percentage of subjects with solicited local and systemic AEs will be assessed for 7 days following each vaccination in the QIVc group and in the comparator group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of subjects with unsolicited AEs</measure>
    <time_frame>28 days following each vaccination</time_frame>
    <description>Percentage of subjects with any unsolicited AEs will be assessed in the QIVc group and in the comparator group until 28 days after each vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of subjects with SAEs, NOCDs, AEs leading to withdrawal from the study or vaccination</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Percentage of subjects with serious AEs (SAE), new onset of chronic disease (NOCD), AEs leading to withdrawal from the study or vaccination, and all medications associated with these events will be reported in the QIVc group and in the comparator group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of subjects with medically-attended AEs</measure>
    <time_frame>30 days following ILI onset</time_frame>
    <description>Percentage of subjects with medically-attended AEs within 30 days after ILI onset will be reported in the QIVc group and in the comparator group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3830</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Seqirus QIVc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell-derived Quadrivalent Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-influenza Comparator (NesiVac-C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIVc</intervention_name>
    <description>QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.</description>
    <arm_group_label>Seqirus QIVc</arm_group_label>
    <other_name>Flucelvax Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, all subjects must meet all of the inclusion criteria&#xD;
        described.&#xD;
&#xD;
          -  Individuals of 6 through 47 months of age on the day of informed consent.&#xD;
&#xD;
          -  Individuals whose parent(s)/Legally Acceptable Representative (LAR) have voluntarily&#xD;
             given written informed consent after the nature of the study has been explained&#xD;
             according to local regulatory requirements, prior to study entry.&#xD;
&#xD;
          -  Individuals who can comply with study procedures including follow-up.&#xD;
&#xD;
          -  Individuals in generally good health as per the Investigator's medical judgement.&#xD;
&#xD;
        Prior to receipt of second study vaccination, subjects must be evaluated to confirm that&#xD;
        they are eligible for subsequent vaccination. If subjects do not meet the criteria of the&#xD;
        original inclusion criteria listed above, they should not receive additional vaccinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute (severe) febrile illness. Enrollment could be considered if the fever is absent&#xD;
             for 72 hours.&#xD;
&#xD;
          -  History of any anaphylaxis, serious vaccine reactions or hypersensitivity, including&#xD;
             allergic reactions, to any component of vaccine or medical equipment whose use is&#xD;
             foreseen in this study.&#xD;
&#xD;
          -  Clinical conditions representing a contraindication to intramuscular vaccination and&#xD;
             blood draws. These may include known bleeding disorders, or treatment with&#xD;
             anticoagulants in the 3 weeks preceding vaccination.&#xD;
&#xD;
          -  A known history of Guillain-Barré Syndrome or other demyelinating diseases such as&#xD;
             encephalomyelitis and transverse myelitis.&#xD;
&#xD;
          -  Abnormal function of the immune system resulting from a clinical condition&#xD;
&#xD;
          -  Received influenza vaccination or has had documented influenza disease in the last 6&#xD;
             months prior to informed consent.&#xD;
&#xD;
          -  Prior vaccination to prevent Neisseria meningitides serogroup C disease or prior&#xD;
             infection caused by this organism.&#xD;
&#xD;
        Additional eligibility criteria may be discussed by contacting the site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>10007-MHAT Dr. Stamen Iliev AD</name>
      <address>
        <city>Montana</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10003-UMHAT Dr. Georgi Stranski EAD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10002-UMHAT Sveti Georgi EAD</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10006-UMHAT-Plovdiv AD</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10004-SHATPPD Dr Dimitar Gramatikov Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20303-MUDr. Stefan Hrunka, Prakticky lekar pro deti a dorost</name>
      <address>
        <city>Chlumec Nad Cidlinou</city>
        <zip>503 51</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20301-MUDr. Daniel Drazan, Prakticky lekar pro deti a dorost</name>
      <address>
        <city>Jindřichův Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20304-MUDr. David Zeman s.r.o.</name>
      <address>
        <city>Ostrava-poruba</city>
        <zip>708 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20302-MUDr. Daniela Pniakova s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>20305-MUDr. Iva Madejova, Prakticky lekar pro deti a dorost</name>
      <address>
        <city>Pardubice</city>
        <zip>530 09</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23305-Vee Family Doctor's Centre</name>
      <address>
        <city>Paide</city>
        <zip>72713</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23301-Innomedica OÜ</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23304-Merelahe Family Doctors Center</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23303-Al Mare Perearstikeskus OU</name>
      <address>
        <city>Tallin</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>23302-Clinical Research Centre</name>
      <address>
        <city>Tartu</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>34001-Demedica</name>
      <address>
        <city>San Pedro Sula</city>
        <zip>21104</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>34003-Clínica Médica y Dental CLIMEDENTY</name>
      <address>
        <city>Tegucigalpa</city>
        <zip>11101</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>34002-Inversiones en Investigación Médica (INVERIME)</name>
      <address>
        <city>Tegucigalpa</city>
        <zip>2449</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>42802-OLVI Medical Centre</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV 1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45804-Clinical Research Centre (CRC), Hospital Tuanku Fauziah</name>
      <address>
        <city>Kangar</city>
        <state>Perlis</state>
        <zip>01000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45803-Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45802-Hospital Sibu</name>
      <address>
        <city>Sibu</city>
        <state>Sarawak</state>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45805-Klinik Kesihatan Putrajaya Presint 9</name>
      <address>
        <city>Putrajaya</city>
        <state>Wilyah Persekutuan Putrajaya</state>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>45801-University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55403-Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55401-Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60808-University of the Philippines Manila Development Foundation Inc</name>
      <address>
        <city>Ermita</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60810-UERM Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Quezon</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60806-Mary Chiles General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61605-Osrodek Badan Klinicznych IN-VIVO sp. z o.o.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61603-Jerzy Brzostek Prywatny Gabinet Lekarski</name>
      <address>
        <city>Dębica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61607-Gdanskie Centrum Zdrowia Sp. z o.o.</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61604-Hanna Czajka, Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Kraków</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61608-Gabinet Lekarski Bartosz Korczowski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61602-Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice</name>
      <address>
        <city>Siemianowice Śląskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61601-ETG Network- Skierniewice,Clinmed Research</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61609-Szpital im. Swietej Jadwigi Slaskiej w Trzebnicy</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>64201-SC Sana Monitoring SRL.</name>
      <address>
        <city>Bucuresti</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>64202-Spitalul Municipal Caracal</name>
      <address>
        <city>Caracal</city>
        <zip>235200</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>64205-Sc Med Fam Apolo srl</name>
      <address>
        <city>Călăraşi</city>
        <zip>910160</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>64206-S.C Centrul Clinic Mediquest S.R.L</name>
      <address>
        <city>Sângeorgiu De Mureş</city>
        <zip>547530</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>76405-Phramongkutklao Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>76401-Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>76404-Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80404-Reg Mun NPE Chernivtsi RCCH Infectious Dept for Infants SHEI of UBSMU</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80405-CI Dnipro Children's City CH #5 of Dnipro City Council</name>
      <address>
        <city>Dnipro</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>80401-Vinnytsia RCCH Policlinic Dept Vinnytsia M.I.Pyrogov NMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Honduras</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Bangladesh</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

